Introduction
The series of Berlin-Frankfurt-Mü nster (BFM) trials for acute lymphoblastic leukemia (ALL) was preceded by a clinical trial with a new intensive multi-agent approach known as the 'WestBerlin study' performed from 1970 to 1976. 1, 2 The study was based on the results from research on drug resistance and on the first observations that long-term remissions of ALL can be achieved by using drug combinations and central nervous system (CNS) irradiation. 3 The probability of event-free survival (EFS) at 5 years was 55% (±6%) in this trial, which was achieved by an 8-week remission induction regimen ('Protocol I') combining the eight most effective antileukemic agents known at that time. The regimen also comprised cranial or craniospinal irradiation followed by antimetabolite-based maintenance therapy. In study ALL-BFM 76, introduction of the re-intensification element 'Protocol II' (which was basically a repetition of the induction element) for all high-risk (HR) patients significantly improved the outcome for these patients, 4 leading to implementation of a re-intensification element ('Protocol III') in trial ALL-BFM 79 also for standard-risk (SR) patients. [5] [6] [7] The concept of delayed intensification was probably one of the most significant contributions to all antileukemic regimens for ALL worldwide. [8] [9] [10] Vincristine/prednisone pulses in maintenance therapy had shown no significant benefit in SR patients in ALL-BFM 79 (randomized study) and were no longer used. 11 Results of the subsequent trials between 1981 and 2000 are presented here.
The fourth BFM trial, ALL-BFM 81, used a new stratification system, the BFM risk factor (BFM-RF), reflecting the cell mass in peripheral blood (PB), liver and spleen at diagnosis. 12 The two randomized questions in this trial focused on reduction of treatment toxicity: (1) Is intravenous (IV) intermediate-dose methotrexate (ID-MTX, 0.5 g/m 2 /24 h Â 4) combined with intrathecal (IT) MTX as effective as 18-Gy preventive cranial radiotherapy (pCRT) in SR patients (BFM-RFo1.2)? and (2) Can the total treatment duration be shortened by 6 months of maintenance therapy from 24 to 18 months? 13 In addition, overall improvement was sought by increasing anthracycline dose from 25 to 30 mg/m 2 and in HR patients by introducing an extended re-intensification element. 8 In study ALL-BFM 83, patients were stratified as in the previous trial and the study focused again on reduction of treatment burden in SR patients with the following randomized questions: (1) Can the 4-week re-intensification element Protocol III be omitted in the 28% of patients defined as SRlow (SR-L) (BFM-RFo0.8)? (2) Is 12 Gy of pCRT as effective as 18 Gy in SR-high (SR-H) patients (BFM-RF 0.8 to o1.2)? and (3) Can the total treatment duration be shortened from 24 to 18 months (randomization continued from study ALL-BFM 81)? For HR patients (BFM-RF X1.7), a pulse of intensive chemotherapy given before regular induction therapy was tested. To determine whether individual in vivo response to corticosteroids is a prognostic predictor, all patients were exposed to a 7-day prednisone window (with one additional IT MTX dose on day 1). The number of leukemic blasts in PB was centrally evaluated. 14 Extensive data analysis revealed that in approximately 10% of the patients a leukemic blast cell count in PB of 1000 per ml or more on day 8 ('Prednisone poor response', PPR) could be found. This is highly predictive of a particularly high relapse risk. The final outcome of the PPR group was nearly half as good as that of patients who had less than 1000 blasts in PB after the prednisone prephase ('Prednisone good response', PGR).
In ALL-BFM 86, the stratification strategy was extended by additional use of prednisone response. A randomized study question was asked in the large intermediate-risk group: (1) Can the outcome of intermediate-risk patients be improved by an additional late re-intensification element ('Protocol S')? Other treatment modifications were implemented in a non-randomized manner for a historical comparison with the results of the previous trials: (2) ID-MTX was substituted by high-dose MTX (HD-MTX, 5 g/m 2 /24 h Â 4) combined with IT MTX ('Protocol M') for all patients to improve extramedullary disease control, but also to allow further elimination/reduction of pCRT; (3) pCRT was omitted in all SR patients (BFM-RFo0.8) and irradiation dose was reduced to 12 Gy for intermediate-risk patients with BFM-RFo1.2; (4) The anthracycline dose and dose intensity was increased in induction and (5) For HR patients, now mainly identified by PPR and/or induction failure, an experimental, intensive consolidation treatment was initiated ('Protocol E'). 15 Trial ALL-BFM 90 aimed at further reduction of treatment burden for the majority of patients while selectively targeting subgroups with increased risk for treatment failure. Study objectives aimed for a reduction of long-term morbidity by (1) limiting pCRT to medium (MR) and HR patients using a dose of 12 Gy 16 and (2) by using less anthracyclines in induction in all patients; 17 on the other hand, further improvement in outcome was attempted by (3) using higher dose intensity in induction (by combining more drugs in a shorter period of time), (4) by additional use of L-asparaginase (L-ASP) in consolidation (randomization in MR patients) and (5) by treatment of HR patients after induction with short rotating pulses of intensive chemotherapy derived from the BFM relapse strategy. 18 In HR patients, treatment-related morbidity was investigated in a randomized phase-III study of r-metHuG-CSF. 19 In collaboration with the International BFM Study Group (I-BFM-SG), the prognostic significance of minimal residual disease was prospectively evaluated during the course of trial ALL-BFM 90. 20 In trial ALL-BFM 95, the BFM-RF was replaced by a new stratification system based on age, white blood cell count (WBC) at diagnosis, immunophenotype, cytogenetics (presence or absence of the t(9;22) or t(4;11)) and prednisone response. 21 Objectives of trial ALL-BFM 95 were (1) reduction of the daunorubicin dose in induction treatment by 50% in the SR group (SRG); (2) prevention of late relapses observed preferentially in boys with SR ALL by extension of maintenance therapy by 12 months; (3) randomized intensification of the extracompartment/consolidation phase with ID cytarabine in addition to HD-MTX in the medium-risk group; (4) omission of pCRT for all MR patients with non-T-ALL and (5) modification of consolidation/reinduction for HR patients by changing drugs in the block elements, and by re-introduction of Protocol II. In addition, intensification of maintenance therapy by pulses of dexamethasone (DEXA) and vincristine was evaluated in the medium-risk group in a randomized intergroup trial of the I-BFM-SG. 22 Veryhigh-risk patients uniformly defined by several study groups of the I-BFM-SG were analyzed for the impact of allogeneic hematopoetic stem cell transplantation (alloSCT), indicating a benefit in disease-free survival (DFS) from alloSCT for all patients. 23 In HR patients with T-ALL relapse reduction and survival advantage could be demonstrated by use of alloSCT. 24 
Patients and methods

Patients
From April 1, 1981 , to June 30, 2000 , 6982 patients up to 18 years of age were enrolled in participating centers in Germany, Austria and Switzerland. A total of 22, 35, 80, 122 and 114 patients (in total 5.3%) were not eligible in trials ALL- BFM 81, 83, 86, 90 and 95, respectively, according to the protocol criteria, which were participation to pilot studies, treatment with a different protocol, diagnosis and/or treatment performed outside the participating countries, lack of essential data for establishing diagnosis, major medical ailment preventing protocol therapy (patients with Down Syndrome were only excluded if premorbidity prevented protocol therapy), essential data missing to calculate the BFM-RF, ALL as a second malignancy or relapse of previously unrecognized ALL. Thus, 6609 patients were eligible and evaluable for this report: 611 patients in study ALL-BFM 81, 653 in study ALL-BFM 83, 998 in study ALL-BFM 86, 2178 in study ALL-BFM 90 and 2169 in ALL-BFM 95 (Table 1) . For each patient, informed consent was obtained from parents or guardians.
Follow-up monitoring was performed by sending questionnaires to participating centers on a yearly or bi-yearly basis. For patients having reached age 418 years, long-term follow-up since 1998 was organized by the German Childhood Cancer Registry (Institute for Medical Statistics, University of Mainz, Germany).
The median follow-up duration (25%/75% quartiles) was 23.9 years (15.7/26 years) for the 459 patients remaining alive in study ALL-BFM 81. The durations were 21.7 (16.1/23.5), 18.2 (14.2/19.9), 14.0 (12.0/15.7) and 9.0 (7.4/10.3) years, respectively, for trials 86, 90 and 95 . Of all 6609 patients, 1893 patients had a follow-up of X15 years.
Diagnosis
Diagnosis of ALL was established if at least 25% lymphoblasts were present in the bone marrow (BM). BM and PB smears as well as cerebrospinal fluid (CSF) cytospin preparations were reviewed in the study center. CNS involvement was diagnosed if 45 cells/ml were counted in CSF and lymphoblasts were identified, or if intracerebral infiltrates were detected on cranial computed tomography (CNS3). In the more recent ALL-BFM 95 study, the exact CNS status was determined by exact count of blasts and WBC, but also by analyzing whether a traumatic lumbar puncture may have taken place. 25 Immunophenotyping was performed as previously described. 26 Cytogenetic studies were performed using standard techniques. 27 Reverse transcription-PCR-based analysis for MLL/AF4
28 was initiated at the start of ALL-BFM 95. Screening for BCR/ABL 29 and TEL/AML1 30 was performed since November 1992 and May 1996, respectively. Cellular DNA content was determined by flow cytometry as previously described. 31 The DNA index of the leukemic blasts was defined as the ratio of DNA content in leukemic G 0 /G 1 cells to that of normal diploid Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al lymphocytes. A cut-off for DNA index at 1.16 was used to distinguish prognostic categories.
Estimation of the leukemic cell mass at diagnosis (BFM-RF)
The leukemic cell mass was calculated by the equation RF ¼ 0.2 Â log (number of blood blasts/ml þ 1) þ 0.06 Â liver size þ 0.04 Â spleen size (organ size in cm below the costal margin).
12
Response and relapse criteria
Prednisone response (PR) was determined after 7 days of monotherapy with prednisone and one IT dose of MTX on day 1, and was centrally reviewed at the study center. Presence of X1000/ml blasts in PB on day 8 was defined as PPR and o1000/ ml blasts as PGR. 14 BM response was evaluated using aspiration smears on day 33 of induction treatment. Complete remission (CR) was defined as o5% blasts in the regenerating BM, absence of leukemic blasts in blood and CSF, and no evidence of localized disease. Failure to achieve CR after induction was not considered an event. Resistance to therapy (non-response) was defined as not having achieved CR after Protocol I in studies ALL-BFM 81, 83 and 86, or after the third high-dose block in ALL-BFM 90 and 95. Relapse was defined as recurrence of X25% lymphoblasts in BM and/or localized leukemic infiltrates at any site. ALL-BFM 95 SR: Initial WBCo20 000/ml and age at diagnosis X1 and o6 years and no T-ALL and no HR criteria. MR: Initial WBCX20 000/ml and/or age at diagnosis o1 or X6 years, and/or T-ALL and no HR criteria. HR: PPR and/or no CR after induction phase Protocol IA (day 33) and/or evidence of t(9;22) (or BCR/ABL) and/or evidence of t(4;11) (or MLL/AF4).
Risk group definitions
Infants o12 months of age at the time of diagnosis of ALL have been enrolled in trial INTERFANT-99 since 1999. 32 Stratification of patients was based on the prognostic significance of the PR also identified in infant ALL. 33 
Treatment
The treatment procedures in the five trials is schematically shown in Figure 1 . Details regarding dosage and exact timing are provided in the key references published earlier [13] [14] [15] 17, 21 and are provided in Supplementary Tables 1-5. The major study questions addressed in each trial are summarized under section Introduction. The five trials have a common basic backbone derived from the previous BFM concept. 2, [4] [5] [6] The most relevant modifications are pointed out as follows: Figure 1 Treatment outlines of studies ALL-BFM 81-95. *Protocol was amended 2 years after start of study ALL-BFM 86: re-intensification (Protocol II) was introduced for the SRG and maintenance treatment was extended to 24 months for all risk groups. R indicates randomization. For other abbreviations see the text. ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; SRG, standard-risk group.
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Anthracyclines. L-asparaginase. L-ASP (Escherichia coli preparation from Bayer, Leverkusen, Germany) was applied daily in induction at 5000 U/m 2 /day IV (days 1-21) in ALL-BFM 81, but in subsequent trials ALL-BFM 83, 86 and 90 L-ASP was used every 3 days at 10 000 U/m 2 IV, starting day 26 (ALL-BFM 83), day 19 (ALL-BFM 86) or day 12 (ALL-BFM 90 or 95) of induction. In reintensification (Protocol II or III), L-ASP has always been used at 10 000 U/m 2 /day IV twice weekly for weeks 1 and 2. In the case of allergic reactions, Erwinia asparaginase (ERWINASE; Speywood, London, UK), and since trial ALL-BFM 95 PEG-Lasparaginase (ONCASPAR; Medac, Wedel, Germany) also were recommended as substitute. Since study ALL-BFM 90, E. coli L-ASP from Medac increasingly replaced the Bayer product as first-line asparaginase preparation. 17 Since ALL-BFM 95, the E. coli L-ASP dose has been reduced to 5000 IU/m 2 in Protocol I because of the higher activity and toxicity compared with the formerly applied preparation from Bayer. 21, 34, 35 Methotrexate. ID-MTX IV (0.5 g/m 2 Â 4, 24-h infusion) was introduced as part of the extracompartment therapy ( Figure 1 ) in study ALL-BFM 81 for the randomized study in SR patients ( Figure 5a ) and was subsequently used in all strata of study ALL-BFM 83. Since ALL-BFM 86 it has been replaced by HD-MTX (5 g/m 2 /24 h IV, Â 4), which was always followed by leucovorin rescue 36 h (study ALL-BFM 86) and 42 h (studies ALL-BFM 90 and 95) from the start of MTX infusion. HD-MTX has always been used in conjunction with IT MTX 15 or IT triple therapy with MTX, cytarabine (ARA-C) and prednisolone. 17, 21 Prednisone/DEXA. In induction, prednisone has been applied at a daily dose of 2.5 mg/kg or 60 mg/m 2 for 28 days (followed by a tapering-down phase) since trial ALL-BFM 70. 2, 4, 5, 13 Beginning with trial ALL-BFM 83, induction therapy was started with a 1-week prednisone window to evaluate the in vivo response to treatment, and to avoid morbidity from tumor lysis syndrome a stepwise increase to full dose was allowed. Re-intensification. Three different treatment elements have been used for delayed re-intensification ( Figure 1 ): Protocols II, III and IV. Protocol III was a 4-week course without cyclophosphamide, Protocol II was a 6-week (ALL-BFM 81 and 83) or 7-week course (ALL-BFM 86, 90, and 95) containing more DEXA (see above), anthracyclines and vincristine (4 instead of 2 doses, each) than Protocol III; it also comprised 1000 mg/m 2 Â 1 cyclophosphamide. Protocol IV was an 8-week course in which ARA-C and VP-16 had been added upfront to the regular Protocol II; this element was only used in high-risk patients of study ALL-BFM 81.
Cranial radiotherapy. Before IV MTX had been introduced, pCRT or therapeutic CRT was applied during the consolidation phase of Protocol I ('Protocol I, Phase B'). Since study ALL-BFM 83, CRT has been given at the end of re-intensification ( Figure 1 ). In that study, the protective effect of 12 Gy as compared with that of 18 Gy pCRT for SR-H patients was analyzed by randomization. Doses of CRT have been reduced since ALL-BFM 81, and pCRT was first eliminated for SR-L patients of study ALL-BFM 83. Study ALL-BFM 90 used only 12 Gy pCRT in all non-standard-risk patients; SR patients did not receive pCRT. In trial ALL-BFM 95, pCRT had been eliminated in non-T-ALL except for the few HR patients (approximately 7% of all non-T patients); high-risk patients and all patients with T-ALL were treated with 12 Gy pCRT. The dose for therapeutic CRT was reduced stepwise from 30 Gy (plus 24 Gy spinal irradiation) in trial ALL-BFM 81 to 18 Gy in ALL-BFM 95 (dose age-adjusted).
IT treatment. IT MTX in the ALL-BFM trials has always been applied only during the intensive phases of therapy, not in maintenance therapy. Thus, seven doses were given in ALL-BFM 81, eight doses in ALL-BFM 83, nine doses in study ALL-BFM 86 and 11 doses in studies ALL-BFM 90 and 95 (for HR patients three doses of IT MTX and nine doses of IT triple therapy were applied in ALL-BFM 90, and five doses of IT MTX and six doses of IT triple therapy in ALL-BFM 95). CNS-positive patients (CNS3) received two additional doses of IT MTX in induction and re-intensification, each.
Duration of treatment elements and maintenance therapy. As shown in Figure 1 , the duration of induction (Protocol I) varied between 8 weeks in ALL-BFM 81, 11 in ALL-BFM 83, 10 in ALL-BFM 86 and 9 weeks in studies ALL-BFM 90 and 95. Maintenance therapy was based on MTX (orally, 20 mg/m 2 once a week) and 6-mercaptopurine (6-MP) (orally, 50 mg/m 2 daily). Total duration of treatment was investigated by randomization in studies ALL-BFM 81 and 83. When the advantage of 24 months' total treatment duration became evident, treatment duration in the subsequent study ALL-BFM 86 was extended to 24 months (18 months planned at the start of the trial). In ALL-BFM 95 the total duration of treatment was extended to 36 months for boys of the SRG. 21 Vincristine/ DEXA pulses in maintenance therapy were only used in the MRG in ALL-BFM 95 in a randomized intergroup trial of the I-BFM-SG. 22 Treatment of HR patients. In ALL-BFM 90, post-induction therapy was changed for HR patients by introducing a consolidation therapy with nine intensive rotational elements consisting of three different 6-day-long pulses of high-dose chemotherapy (HR-1, HR-2 and HR-3), which were given three times, starting after Phase A of Protocol I. These elements were derived from the ALL-BFM REZ relapse strategy. 18 In ALL-BFM Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al 95, these high-dose blocks were modified (HR-1 0 , HR-2 0 and HR-3 0 ) and the re-intensification element Protocol II was reintroduced, replacing the seventh to the ninth high-dose block. Since ALL-BFM 95 all patients have received prophylactic Granulocyte-Colony Stimulating Factor (G-CSF) after each HR pulse.
Stem cell transplantation. AlloSCT performed by BM transplantation was first introduced in study ALL-BFM 86 for selected patients. Subsequently, in studies ALL-BFM 90 and 95 this was more uniformly applied. Patients were clearly defined through criteria mainly derived from univariate and multivariate risk factor analysis, which had been performed with the results of all patients (n ¼ 998) treated in study ALL-BFM 86. 15, 36 A prospective approach of the I-BFM-SG also tried to uniformly define the conditioning regimen and immunosuppressive therapy. 23 AlloSCT in first CR remains a rare procedure, with only 27 patients transplanted in trial ALL-BFM 90 (1.2%) and 58 patients in trial ALL-BFM 95 (2.7%).
Statistical analysis
EFS was defined as the time from diagnosis to the date of last follow-up in CR or first event. Events were resistance to therapy (non-response), relapse, secondary neoplasm or death from any cause. Failure to achieve remission due to early death or nonresponse was considered as events at time zero. Survival (SUR) was defined as the time from diagnosis to death from any cause or last follow-up. For analysis of randomized patient subsets, DFS was calculated from the time of randomization to the first event or the last follow-up date. Patients lost to follow-up were censored at the last contact. The Kaplan-Meier method was used to estimate the SUR rates, 37 with differences compared using two-sided log-rank test. 38 Cox proportional hazards model was used for uni-and multivariate analyses. 39 Cumulative incidence (CI) functions for competing events were constructed by the method of Kalbfleisch and Prentice, 40 and were compared with the Gray's test. 41 Comparisons of randomized groups are presented as intent-to-treat analyses. A CNS relapse is defined as an isolated CNS relapse or a CNS relapse in combination with another type of relapse or failure.
Results
Treatment results by study and according to presenting features
The overall results of all five multicenter ALL-BFM trials are presented in Table 1 Tables 2-6 .
Initial patient characteristics (Tables 2-6 ) did not show major differences between study cohorts. This is not too surprising as at least in Austria and Germany basically all patients with malignant disease are recorded, and then also registered in one of the cooperative clinical studies. It is guaranteed that all patients enrolled with ALL in one of the participating centers will be treated according to study plan if informed consent has been provided by parents or guardians. A few small differences should be pointed out. Immunphenotyping in trial ALL- BFM 81 (from 1981 BFM 81 (from -1983 was not yet fully developed, and thus any comparison of prevalence and outcome of T-ALL with the more recent studies should be made with caution. In 1998, the first patients with infant ALL (age at diagnosis p12 months) were started to get enrolled in study Interfant-99 32 and thus only 19 patients were treated in study ALL-BFM 95.
A direct comparison of the five consecutive studies performed from 1981 to 2000 indicates that there has been an increase in EFS and SUR (Figures 2a and b) . The second study in this series, ALL-BFM 83, provided a slightly inferior result when compared with the previous study ALL-BFM 81: 10-year probability of event-free survival (pEFS) was 63% (s.e. 2%) in ALL-BFM 83 as compared with 65% (s.e. 2%) in ALL-BFM 81. Subsequently, there has been a steady increase in EFS and SUR. The results in Table 1 indicate that this improvement is due to a reduction in systemic and CNS relapses. The CI at 10 years (10-year CI) of any relapse with CNS involvement dropped from 9% (5% isolated CNS relapse) in study ALL-BFM 81 to 3% (1% isolated CNS relapse) in study ALL-BFM 90, the lowest 10-year CI for CNS relapse ever achieved in ALL-BFM trials (Figure 2a ). CI at 10 years for any CNS recurrence was 4% (1.8% isolated) in the most recent study ALL-BFM 95. Various changes in therapy, for example, introduction of HD-MTX with 5 g/m 2 (since study ALL-BFM 86) and increased dose intensity in induction therapy (studies ALL-BFM 90 and 95) did not increase the overall death rate ( Table 1) : 10-year CI was only 2.1% (s.e. 0.3%) in study ALL-BFM 95. Probability of SUR at 10 years (10-year pSUR) in that study was 85% (s.e. 1%).
The largest advances were seen in patients 1-9 years of age, with low WBC (o10 000/ml), and non-T-ALL patients who were SR according to the National Cancer Institute criteria (NCI-SR). In study ALL-BFM 95, patients with non-T NCI-SR ALL achieved a 10-year pEFS of 85.6% and 10-year probability of survival (pSUR) of 92.2% (s.e. 0.8%). In the corresponding subset of NCI-SR ALL with T-cell disease, studies ALL-BFM 81, 86, and 95 have been the most effective ones. The last trial produced a 10-year pEFS for NCI-SR T-ALL of 88.5% and a 10-year pSUR of 91.6% (s.e. Treatment outcome according to initial response to prednisone (and one-dose IT MTX)
Since ALL-BFM 86 PR has been used for stratification. Thus, the individual in vivo sensitivity was an add-on criterion to identify HR patients, independent of any presenting feature except induction failure and/or presence of t (9;22) . The group of patients with PPR is small and comprises 8.4-9.5% of all patients . We compared the outcome of patients with good or poor response to prednisone (PGR/PPR) in non-T-ALL and T-ALL, respectively (Figures 3a-d) . In the largest subset, with non-T-ALL patients with PGR (Figure 3a) , studies ALL-BFM 90 and 95 produced nearly identical results (10-year pEFS 81 and 80%, respectively), which was superior to that of study ALL-BFM 86 (10-year pEFS 72%). This was in part due to omission of reintensification in the SRG in the first phase of ALL-BFM 86 prior to knowledge about the impact of that treatment phase even in low-risk patients. 11 Another contributing factor may have been the more condensed induction therapy in trial ALL-BFM 90. 17 If results of T-ALL patients with PGR are compared (Figure 3b) , a rather homogeneous outcome pattern can be found: Studies ALL-BFM 86 and 95 yielded 10-year pEFS of 82 and 85%, respectively, while 10-year pEFS in study ALL-BFM 90 was slightly inferior at 75%. The corresponding CIs for relapses with Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al CNS involvement were below 5% and similar in all three studies, both for non-T-ALL and T-ALL with PGR (Figures 3a and b) . If outcome in the small subgroups of patients with PPR and non-T-ALL are compared, larger differences can be found, both for 10-year pEFS and CI of CNS relapses (Figure 3c ). Study ALL-BFM 95 was the most effective one (10-year pEFS 57%, CI for any CNS relapse 1% (s.e. 1%)). A similar result was found for T-ALL patients with PPR in study ALL-BFM 95. In that subgroup, however, study ALL-BFM 90 was quite unsuccessful to control systemic relapse, probably due to the suboptimal composition of the re-intensification pulses and lack of delayed intensification (Protocol II) for HR patients (Figures 1 and 3d) .
Protocol-specific treatment outcome and randomized questions
In both studies ALL-BFM 81 and 83, all patients were eligible for a randomization of 6-month maintenance therapy (18 versus 24 months total treatment duration). A total of 764 patients were randomized and the results for DFS and SUR are shown in Figures 4a and b . With this long follow-up, the difference in 10-year pDFS has lost its statistical significance (P ¼ 0.069). Only considering late events, which occurred more than 10 years after diagnosis in both arms, it is of interest that in the group treated for 18 months no late relapses, two deaths in first CR and four secondary neoplasms were recorded. In the group treated ) pSUR. ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CI, cumulative incidence; CNS, central nervous system; pEFS, probability of event-free survival; pSUR, probability of survival.
Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al by six additional months of maintenance therapy (6-MP and MTX), three relapses, two deaths in first CR and nine secondary neoplasms were reported (Figure 4a ). The SUR data suggest that approximately one-third of the recurrences could be rescued by salvage therapy (Figure 4b) .
In study ALL-BFM 81, a randomized study question with 279 patients focused on whether pCRT can be replaced by ID-MTX (500 mg/m 2 /24 h IV) (and IT MTX). As shown in Figure 5a , this attempt did not succeed even though the randomization only comprised patients of the SRG (for definition see above). Patients who were treated with ID-MTX and without pCRT suffered approximately five times higher rate of CNS relapse (10-year CI 14% as compared with 3% for irradiated patients). Disease control was, however, efficient for SR-L patients without irradiation. In the subsequent study ALL-BFM 83, pCRT was therefore eliminated for SR-L patients, and could safely be replaced by ID-MTX (data not shown). For SR-H patients of study ALL-BFM 83, the experience from the preceding study ALL-BFM 81 prompted the randomized question whether 12 Gy is as effective as 18 Gy for pCRT. Both groups received pCRT at the end of re-intensification, thus, after four courses of ID-MTX and IT MTX (Figure 1 ). Figure 5b demonstrates that 12 Gy was as effective as 18 Gy.
Study ALL-BFM 83 evaluated whether it was possible to reduce treatment burden through elimination of re-intensification for SR-L patients comprising nearly 30% of all patients considered to have the lowest relapse risk. Figure 6a clearly demonstrates that re-intensification is a very essential element of antileukemic treatment, which is required both for prevention of systemic and extramedullary recurrences. When the subsequent study ALL-BFM 86 was planned and then initiated, this finding was not yet evident. Thus, it was assumed to be safe to omit re-intensification, in particular, as in that study HD-MTX had been introduced for all patients. Eventually, approximately 2 years into the trial, the critical findings of the randomized trial in ALL-BFM 83 became evident. Immediately, study ALL-BFM 86 was amended and treatment with re-intensification was re-introduced. Figure 6b displays the poor outcome of those SR patients who had not received Protocol II as compared with the subsequent cohort of patients fully treated with re-intensification. Abbreviations: ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CNS, central nervous system; HR, high risk; MR, medium risk; pEFS, probability of event-free survival; pSUR, probability of survival; SR, standard risk; WBC, white blood cell count; s.e., standard error. a NCI-SR: Age X1 and o10 years and WBCo50 000/ml; NCI-HR: age X10 years or WBCX50 000/ml. Infants o1 year were excluded from the NCI definition.
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Interestingly, these patients did not show significant increase in CNS relapses (Figure 6b ), in contrast to the corresponding cohort of study ALL-BFM 83 (Figure 6a ). pSUR at 10 years for SR patients of study ALL-BFM 86 was 78% when treated without reintensification, as compared with 91% when re-intensification had been given (P ¼ 0.002). This indicates that the salvage therapy succeeded in a rather large percentage of undertreated patients.
In study ALL-BFM 90, 1085 patients of the large intermediaterisk group were randomized for additional asparaginase treatment (25 000 IU/m 2 Â 4 q2w, given IV or intramuscularly) during Protocol M (Figure 1 ). The number of events was identical in both the groups yielding a 10-year pEFS of 80% (s.e. 2%), each.
In study ALL-BFM 95, 1032 patients of the newly defined intermediate-risk group were randomized to receive or not a Abbreviations: ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CNS, central nervous system; HR, high risk; MR, medium risk; pEFS, probability of event-free survival; pSUR, probability of survival; SR, standard risk; WBC, white blood cell count; s.e., standard error.
24-h infusion of ARA-C given immediately after 24-h infusion of HD-MTX. 21 While hematological toxicity was significantly higher in the randomization group with additional ARA-C (arm MCA), no reduction in relapses could be achieved: the 10-year CI of relapses was 19% (s.e. 2%) for arm M (no ARA-C) and 18% (s.e. 2%) for MCA (plus ARA-C); 10-year pDFS was 81% (s.e. 2%) for both arms.
Discussion
Clinical trials on childhood ALL have successfully evolved over more than three decades. 42 They have generated a wealth of data, which can be used for risk assessment and clinical consultation on a daily basis. The treatment platforms vary between study groups, but in a given structure Abbreviations: ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CNS, central nervous system; HR, high risk; MR, medium risk; pEFS, probability of event-free survival; pSUR, probability of survival; SR, standard risk; WBC, white blood cell count; s.e., standard error.
Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al they may also serve as a reliable key reference for innovative research projects. The design of the clinical studies of the ALL-BFM study group has always focused on the intention to give as little therapy as possibly needed to prevent recurrence in the largest number of children. The concept to develop risk-adapted therapy is rather easy if treatment is intensified moderately, but not without drawbacks if treatment is decreased. Impressive examples now Abbreviations: ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CNS, central nervous system; HR, high risk; MR, medium risk; pEFS, probability of event-free survival; pSUR, probability of survival; SR, standard risk; WBC, white blood cell count; s.e., standard error.
Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al with long follow-up are shown in this report (Figures 4, 5a and 6) . 11, 15, 16, 43 The data on late effects and secondary malignancies make it mandatory to attempt further de-escalation of therapy. [44] [45] [46] [47] [48] [49] While there is general agreement that pCRT should nowadays be limited to very small subsets of ALL patients, 21 or maybe even eliminated as suggested by some investigators, 50 Abbreviations: ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CNS, central nervous system; HR, high risk; MR, medium risk; pEFS, probability of event-free survival; pSUR, probability of survival; SR, standard risk; WBC, white blood cell count; s.e., standard error.
Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al one needs to watch the side effects of replacement therapies, which is oftenFfor CNS controlFbased on large doses of DEXA and intensive IT therapy. 51, 52 When analyzing the different treatment components, the following conclusions can be drawn from a BFM point of view:
(1) Shorter maintenance therapy is not as effective as the 24-month therapy routinely given today ( Figure 4) . It is interesting, however, that even only 6 months of maintenance therapy appear to be sufficient in some subsets. 53 We have recently demonstrated that boys in particular with SR ALL may have some benefit from additional maintenance therapy, but secondary malignancies may be an issue. 21, 47, 54 Pharmacogenetic disposition may influence the efficacy of antimetabolite therapy, but is relevant for other treatment phases as well. [55] [56] [57] [58] [59] In the frame of a large intergroup study for intermediate-risk ALL, we were able to clearly demonstrate that pulses with DEXA and vincristine given every 10 weeks ( Â 6) on top of regular maintenance therapy with 6-MP and MTX do not provide any benefit for EFS or SUR if a chemotherapy backbone as in ALL-BFM 95 is applied. 22 (2) Omission of delayed intensification turns an SR leukemia into HR leukemia (Figure 6a and b) . Protocol II has proven to be one of the most important treatment elements for childhood ALL. [9] [10] [11] 15 In some subgroups, repetition of re-intensification with Protocol II has been effective in preventing even more relapses. 60, 61 (3) Intensive consolidation (Protocol E in ALL-BFM 86, modified HR blocks in ALL-BFM 95) and delayed re-intensification (Protocol II) appear to be essential in particular in prednisone-resistant HR patients (Figures 3c and d) . Probably, sensitivity to alkylating agents and antimetabolites is crucial in that treatment phase. Add-on therapy (augmented BFM concept) has also shown to increase the efficacy of that phase. 62 In HR patients any intervention can be monitored very efficiently through quantitative PCR detection of minimal residual disease. 20, 63, 64 (4) Interim consolidation (also called interim maintenance):
Since study ALL-BFM 86, this phase is called Protocol M, because four courses of HD-MTX are given on top of an 8-week antimetabolite phase with 6-MP. While the role of HD-MTX has not been evaluated by randomized studies, it is of interest that this element allowed the BFM investigators to eventually reduce and eliminate pCRT for the majority of patients with non-T-ALL without having to introduce IT MTX in maintenance therapy. Thus, the BFM trials so far succeeded to limit the more intensive therapy phases to Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al about 6 months. After that, no treatment is given except oral 6-MP and oral MTX. This point is often not mentioned when treatment burden is being discussed. (5) Special subgroups and response: In vivo sensitivity to prednisone has proven to be a robust predictor of disease recurrence even in rare subgroups of ALL, such as infant ALL, Ph þ ALL and T-cell ALL. 15, 33, 65 The percentage of patients found prednisone resistant may vary, but the prognosis is uniformly inferior to that of the corresponding patients with PGR. PPR can be used to adapt treatment intensity, 17, 21, 32 to identify HR subsets of Ph þ ALL 65, 66 and to target alloSCT to very-high-risk subgroups of T-ALL. 24 (6) The role of alloSCT in first CR is limited to very-high-risk patients. Due to the specific toxicities associated with this procedure, indications must be clearly defined and the conditioning and immunosuppressive regimen should also be performed within clinical trials to allow evidence-based adaptations in the future. ) pSUR. ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; pDFS, probability of disease-free survival; pSUR, probability of survival; s.e., standard error.
Long-term follow-up in five consecutive ALL-BFM trials A Möricke et al or molecular mechanisms, which determine disease, resistance and recurrence. [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] While in the era of genomics the number of papers in the field of leukemia has risen amazingly, it remains difficult to filter out the information, which can be used for improved treatment quality and better prevention of disease recurrence. Certainly one prerequisite is reproducibility of data, and thus, uniform approaches are needed if such techniques shall be used routinely in clinical diagnostics and for risk assessment. SR-H/1: pCRT with 12 Gy; SR-H/2: pCRT with 18 Gy. ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CI, cumulative incidence; CNS, central nervous system; ID-MTX, intermediate-dose methotrexate; IV, intravenous; MTX, methotrexate; pCRT, preventive cranial radiotherapy; pEFS, probability of event-free survival; s.e., standard error; SR, standard risk; SR-H, standard risk high.
Till date, precise determination of treatment response through quantitative MRD measurement is the most advanced tool to adapt treatment intensity to an individual's genetic variation and to leukemia-specific resistance mechanisms. 56, 63, 64, [80] [81] [82] who participated in this trial, the physicians and nurses of all hospitals for their input in performing this study and the study committee for productive discussions during the development and Impact of reintensification, pEFS and CI of CNS relapse. ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Mü nster; CI, cumulative incidence; CNS, central nervous system; pEFS, probability of event-free survival; s.e., standard error; SR, standard risk; SRG, standard-risk group; SR-L, standard risk low.
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